Measuring the diffusion of water within bone tumors may indicate whether the tumors, caused by the metastasis of prostate or breast cancer, are responding to treatment, according to preclinical research at the University of Michigan Comprehensive Cancer Center.
Measuring the diffusion of water within bone tumors may indicate whether the tumors, caused by the metastasis of prostate or breast cancer, are responding to treatment, according to preclinical research at the University of Michigan Comprehensive Cancer Center.
The developers of the technique have previously carried out MR functional diffusion mapping in people with brain tumors, finding that the test can identify patients who are responding to chemotherapy or radiation after only three weeks of therapy - more than two months earlier than traditional tests. If their most recent work can be translated to the clinic, the newly developed technique could fill a gap in the management of patients with cancers that have spread to the bone.
"Currently, we have no way of detecting bone tumor response to therapy," said Brian D. Ross, Ph.D., a professor of radiology and biological chemistry. "The magnitude of this problem is huge - as many as 500,000 people in the U.S. have metastatic breast or prostate cancer to the bone."
Ross, codirector of the molecular imaging program at the UM Comprehensive Cancer Center, and Alnawaz Rehemtulla, Ph.D., a professor of radiation oncology and environmental health sciences, have founded a company in Ann Arbor, called ImBio, that has licensed the commercialization rights of the diffusion technique from the university. Their software, which tracks the movement of water in bone, runs on Cedara Software's I-Response workstation, which is being developed by the Merge Healthcare subsidiary specifically to serve as a platform on which radiologists and radiation oncologists can work together.
The UM researchers used I-Response in their preclinical studies. Cedara continues to develop the platform for commercial release to OEMs later this year, according to Chris Wiedmann, Cedara product manager for oncology.
"I-Response will provide the framework for the technology and workflow of functional diffusion mapping," he told DI SCAN.
In studies on mice, functional diffusion mapping using MR and the specially designed software tracked bone water diffusion during the course of the animals' chemotherapy. Because tumor cells slow the movement of water, the death of these cells is accompanied by an increase in water diffusion. An increase in diffusion, therefore, indicated effectiveness of the treatment in this animal model of prostate cancer metastasis.
In the study, which was reported in the April 15 issue of Cancer Research, untreated mice showed little or no change in water diffusion, while the functional diffusion map changed increasingly in the treated mice over the three weeks of their therapy. Using functional diffusion map analysis, the researchers identified a statistically significant change in diffusion as early as seven days after the start of treatment. At the end of the study, they removed the tumors and found the functional diffusion map predicted the tumors' response to treatment.
Tumors or portions of a tumor that showed no change on the functional diffusion map showed no changes in specimens removed from the animals. The map accurately predicted the cells that were responsive to the chemotherapy.
"The functional diffusion map could serve as an early biomarker indicating that a tumor is responding to treatment," said author Dr. Kenneth Pienta, director of the urologic oncology program at the UM Comprehensive Cancer Center. "This could allow patients to switch to an alternative therapy without wasting time on a treatment that is not working."
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.